- WELL and HEALWELL AI have launched the second-generation
of WELL AI Decision Support ("WAIDS"), which now features advanced
chronic disease screening for diseases like chronic kidney disease,
hypertension, and diabetes, enabling patient risk
stratification.
- The updated WAIDS tool identifies over one hundred
diseases and delivers actionable clinical insights at the point of
care, contributing to the management of chronic disease-related
costs in Canada, which are
estimated to be approximately $190
billion annually and affected 45.1% of all Canadians in
2021.
VANCOUVER, BC AND TORONTO, May 2,
2024 /CNW/ - WELL Health Technologies Corp. (TSX: WELL)
(OTCQX: WHTCF) ("WELL"), a digital health company focused on
tech-enabling healthcare providers, and its investee company,
HEALWELL AI (TSX: AIDX) ("HEALWELL"), are pleased to
announce the launch of the second generation WELL AI Decision
Support, (or "WAIDS"). This enhanced version which features
advanced chronic disease screening arrives just six months after
the initial launch, which was primarily focused on rare disease
detection.
The upgraded WAIDS now includes screening capabilities for
numerous chronic diseases such as chronic kidney disease,
hypertension, and diabetes, enabling risk stratification of
patients into high, medium, or low risk categories. This expansion
broadens WAIDS's utility in detecting more than one hundred rare
and chronic diseases, providing clinically validated insights that
identify care gaps and equip clinicians with actionable information
at the point of care.
Dr. Michael Frankel, Chief
Medical Officer of WELL, commented on the new capabilities "Adding
chronic disease detection is a game-changer for our AI powered
physician co-pilot tools. I have personally used this tool in my
practice and found it to be of tremendous help and support. The
tool compliantly scans my data and provides me with an overview of
a number of key diseases as well as insights on which patients
could be at higher risk or exposure to such diseases."
The technology behind WAIDS is powered by HEALWELL AI who has
been helping physicians save lives for the past four years with its
best-in-class rare disease detection capabilities. This launch
represents another significant step forward in WELL and HEALWELL's
ongoing collaboration to transform healthcare through data science
and innovative technology.
"HEALWELL is committed to continuously advancing its data
science offerings, and with WAIDS, we aim to serve as a vital
co-pilot in the medical community," said Dr. Alexander Dobranowski, CEO of HEALWELL. "The
second generation of WAIDS is designed to enhance and support the
critical decision-making processes of doctors, ensuring they remain
central to patient care. Historically, HEALWELL's focus has been on
screening for rare and ultra rare diseases, but now with the second
generation WAIDS we have significantly expanded our capabilities to
finding patients with important chronic diseases. This adds
tremendous value to patients, practitioners and healthcare
systems."
According to a Statistic's Canada report in 2023 on the Health of
Canadians1, 45.1% of Canadians lived with at least one
major chronic disease in 2021. Chronic diseases and the percentage
of Canadians who have them include conditions like Diabetes 11%,
Chronic Obstructive Pulmonary Disease 10%, Heart Disease 8%, and
Chronic Kidney Disease 11-13%2 . These conditions are
also not found alone and increasingly more and more Canadians are
being found to have a plurality of these morbidities3.
Chronic diseases and related health issues are estimated to cost
the Canadian economy $190 billion
annually4, with $122
billion stemming from indirect income and productivity
losses, and $68 billion in direct
healthcare costs.
For more information on WELL AI Decision Support, please
visit https://decisionsupport.wellhealth.ai/.
Footnotes:
1.
|
https://www.statcan.gc.ca/en/about/smr09/smr09_142
|
2.
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926383/#:~:text=Chronic%20kidney%20disease%20(CKD)%20is,13%25%20of%20the%20population%20globally.
|
3.
|
Steffler, M, et al
(2021). Trends in prevalence of chronic disease and multimorbidity
in Ontario, Canada. CMAJ, 193 (8): E270-7.
|
4.
|
Chronic Disease
Prevention Alliance of Canada. 2018 pre-budget submission to the
House of Commons Standing Committee on Finance August 4, 2017.
Retrieved from
https://www.ourcommons.ca/Content/Committee/421/FINA/Brief/BR9073636/br-external/ChronicDiseasePreventionAllianceOfCanada-e.pdf
|
WELL HEALTH TECHNOLOGIES CORP.
Per: "Hamed Shahbazi"
Hamed Shahbazi
Chief Executive Officer, Chairman and Director
HEALWELL AI INC.
Dr. Alexander Dobranowski
Chief Executive Officer
HEALWELL AI Inc.
About WELL Health Technologies Corp.
WELL's mission is to tech-enable healthcare providers. We do
this by developing the best technologies, services, and support
available, which ensures healthcare providers are empowered to
positively impact patient outcomes. WELL's comprehensive healthcare
and digital platform includes extensive front and back-office
management software applications that help physicians run and
secure their practices. WELL's solutions enable more than 34,000
healthcare providers between the US and Canada and power the largest owned and
operated healthcare ecosystem in Canada with more than 165 clinics supporting
primary care, specialized care, and diagnostic services. In
the United States WELL's solutions
are focused on specialized markets such as the gastrointestinal
market, women's health, primary care, and mental health. WELL is
publicly traded on the Toronto Stock Exchange under the symbol
"WELL" and on the OTC Exchange under the symbol "WHTCF". To learn
more about WELL, please visit: www.well.company.
About HEALWELL AI
HEALWELL is a healthcare technology company focused on AI and
data science for preventative care. Its mission is to improve
healthcare and save lives through early identification and
detection of disease. Using its own proprietary technology, the
Company is developing and commercializing advanced clinical
decision support systems that can help healthcare providers detect
rare and chronic diseases, improve efficiency of their practice and
ultimately help improve patient health outcomes. HEALWELL is
executing a strategy centered around developing and acquiring
technology and clinical sciences capabilities that complement the
Company's road map. HEALWELL is publicly traded on the Toronto
Stock Exchange (the "TSX") under the symbol "AIDX" and on the OTC
Exchange under the symbol "HWAIF". To learn more about HEALWELL,
please visit: https://healwell.ai/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/well-launches-its-second-generation-ai-powered-physician-co-pilot-with-chronic-disease-detection-powered-by-healwell-ai-302134054.html
SOURCE WELL Health Technologies Corp.